中文摘要：

目的：采用高效液相色谱法（HPLC）测定复尔康注射液中维A酸的血药浓度，计算药动学参数，并与维A酸对照品溶液比较其药动学特征。方法：色谱柱：Dikma Kromasil C18（250min×4．6mm，5μm）；流动相：乙腈-0．1％磷酸溶液；流速：1．0ml·min^-1；检测波长：355nm；柱温：30℃；进样量：20μl。结果：复尔康注射液中维A酸和维A酸对照品溶液在家兔体内均符合开放二室动力学模型特征。复尔康注射液中维A酸的t1/2α=10．61min，t1/2β=99．44min，K10=0．022min^-1，AUC=257．15μg·min·ml^-1，CL=0．022mg·kg·min^-1；维A酸对照品溶液的t1/2α=8．61min，t1/2β=54．06min，K10=0．033min^-1，AUC=174．87μg·min·ml^-1，CL=0．032mg·kg·min^-1。结论：与维A酸对照品溶液相比，复尔康注射液中维A酸的消除速率减慢，生物利用度增加，在体内滞留时间延长。

英文摘要：

Objective： To determine the plasma concentration of retinoic acid of Fuerkang injection by HPLC, calculate pharmacokinetics parameters and compare with reference retinoic acid solution. Methods：Column：Dikma Kromasil C18 （250 mm×4.6 mm, 5μm）;Mobile phase： acetonitrile- 0.1%phosphoric acid; Flow rate： 1.0 ml· min^-1; Detection wave length： 355nm;Column temperature：30℃ and sample size was 20μl. Results：Retinoic acid of Fuerkang injection and reference solution showed typical characteristics of open two-compartment dynamic model. Retinoic acid of Fuerkang injection： t1/2α=10.61min, t1/2β=99.44min, K10=0.022min^-1, AUC=257.15μg-min-ml^-1, CL= 0.022mg· kg^-1 min^-1.Reference retinoic acid solution：t1/2α=8.61min, t1/2β=54.06min, K10=0.033min^-1, AUC=174.87μg- min·ml^-1,CL=0.032mg ·kg^-1 ·min^-1. Conclusion： Retinoic acid of Fuerkang injection compared with reference retinoic acid solution, the rate of elimination was slowed, the bioavailability was increased and the retention time in the body was prolonged.